NCT06462729View on ClinicalTrials.gov

LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Degenerative Disc DiseaseLumbar Disc DiseaseSpine DiseaseLumbar Spine Degeneration
Interventions
DEVICE

LDGraft

LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)

DEVICE

LDGraft

LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)

OTHER

Allograft Bone

Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)

Trial Locations (2)

2109

RECRUITING

Macquarie University, Sydney

2305

RECRUITING

Newcastle Private Hospital, Newcastle

Sponsors

Lead Sponsor

Locate Bio Pty Ltd
All Listed Sponsors
lead

Locate Bio Pty Ltd

INDUSTRY

NCT06462729 - LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF) | Biotech Hunter | Biotech Hunter